Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101527 | 0.90 | DDB1 (0.45) | DDB1CRBNGPR119NAMPTKDM4E | |
| SCHEMBL30327907 | 0.81 | DDB1 (0.44) | DDB1CRBNGPR119NAMPTKDM4E | |
| SCHEMBL18075963 | 0.73 | CHRM4 (0.45) | NAMPT | |
| SCHEMBL23145355 | 0.72 | USP2 (0.45) | DDB1CRBNGPR119NAMPTKDM4E | |
| SCHEMBL13617698 | 0.72 | GPR119 (0.41) | DDB1CRBNGPR119NAMPT | |
| SCHEMBL5557834 | 0.71 | SLC6A9 (0.47) | DDB1CRBNGPR119NAMPTKDM4E | |
| SCHEMBL25547332 | 0.71 | GPR119 (0.60) | GPR119NAMPT | |
| SCHEMBL7010905 | 0.71 | USP2 (0.46) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL769732 | 0.71 | USP2 (0.46) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL20942451 | 0.70 | NEK2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428088-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428088-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | DDB1 4415/4885CRBN 3770/4885GPR119 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.